Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) CEO Randall C. Schatzman sold 10,000 shares of the company’s stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $25.16, for a total transaction of $251,600.00. Following the completion of the transaction, the chief executive officer now owns 124,768 shares in the company, valued at approximately $3,139,162.88. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Shares of Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) opened at 32.15 on Monday. The stock’s 50 day moving average is $28.99 and its 200 day moving average is $28.89. Alder BioPharmaceuticals Inc. has a 52-week low of $15.82 and a 52-week high of $39.43. The stock’s market cap is $1.62 billion.

Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.15. During the same period in the prior year, the company posted ($0.62) EPS. On average, equities analysts predict that Alder BioPharmaceuticals Inc. will post ($3.13) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

A number of large investors have recently modified their holdings of ALDR. Prudential Financial Inc. increased its stake in shares of Alder BioPharmaceuticals by 12.5% in the first quarter. Prudential Financial Inc. now owns 104,100 shares of the biopharmaceutical company’s stock worth $2,549,000 after buying an additional 11,600 shares during the last quarter. BlackRock Fund Advisors increased its stake in shares of Alder BioPharmaceuticals by 4.2% in the first quarter. BlackRock Fund Advisors now owns 1,136,823 shares of the biopharmaceutical company’s stock worth $27,841,000 after buying an additional 45,908 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Alder BioPharmaceuticals by 11.4% in the first quarter. JPMorgan Chase & Co. now owns 349,482 shares of the biopharmaceutical company’s stock worth $8,559,000 after buying an additional 35,883 shares during the last quarter. State Street Corp increased its stake in shares of Alder BioPharmaceuticals by 20.2% in the first quarter. State Street Corp now owns 1,195,800 shares of the biopharmaceutical company’s stock worth $29,282,000 after buying an additional 200,566 shares during the last quarter. Finally, Pictet Asset Management Ltd. increased its stake in shares of Alder BioPharmaceuticals by 32.1% in the first quarter. Pictet Asset Management Ltd. now owns 79,800 shares of the biopharmaceutical company’s stock worth $1,515,000 after buying an additional 19,400 shares during the last quarter.

ALDR has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. initiated coverage on Alder BioPharmaceuticals in a research report on Tuesday, September 13th. They issued an “overweight” rating and a $40.00 target price for the company. Jefferies Group reissued a “buy” rating and issued a $61.00 target price on shares of Alder BioPharmaceuticals in a research report on Tuesday, July 19th. BMO Capital Markets initiated coverage on Alder BioPharmaceuticals in a research report on Thursday. They issued an “outperform” rating and a $42.00 target price for the company. Zacks Investment Research raised Alder BioPharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 1st. Finally, Brean Capital reissued a “positive” rating and issued a $45.00 target price on shares of Alder BioPharmaceuticals in a research report on Wednesday, July 27th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Alder BioPharmaceuticals currently has an average rating of “Buy” and a consensus target price of $44.38.

About Alder BioPharmaceuticals

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

5 Day Chart for NASDAQ:ALDR

Receive News & Stock Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.